Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
112 participants
INTERVENTIONAL
2014-09-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease
NCT00506506
Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes
NCT01978405
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
NCT03982160
Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury
NCT01210456
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
NCT00173706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4 patients undergoing computer tomography. Eligible patients were randomly assigned to two groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3 days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR was measured at baseline and 48 hours after procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arginine
Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
L-arginine
Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
Placebo
Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-arginine
Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable CKD stage 3-4 patients
* Patients undergoing elective contrast media injection
Exclusion Criteria
* Acute kidney injury diagnosed within 4 weeks
* Active infection/sepsis
* Severe liver disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Phramongkutklao College of Medicine and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Nephrology, Phramongkutklao Hospital
Rachatevee, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Arginine 01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.